Institute of Medical Sciences, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Foresterhill, Aberdeen, United Kingdom.
Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom.
Front Immunol. 2018 Sep 24;9:2182. doi: 10.3389/fimmu.2018.02182. eCollection 2018.
Head and neck cancers (HNC) represent a heterogeneous cluster of aggressive malignancies that account for 3% of all cancer cases in the UK. HNC is increasing in frequency particularly in the developing world, which is related to changes in risk factors. Unfortunately, the mortality rate is high, which is chiefly attributed to late diagnosis at stages where traditional treatments fail. Cancer immunotherapy has achieved great successes in anti-tumor therapy. Checkpoint inhibitor (CI) antibodies enhance anti-tumor activity by blocking inhibitory receptors to drive tumor-specific T and NK cell effector responses. Since their introduction in 2011, CI antibodies have been approved for many cancer types including HNC. Here, we examine the development of CI therapies and look forward to future developments for treatment of HNC with CI therapies.
头颈部癌症（HNC）是一组异质性的侵袭性恶性肿瘤，占英国所有癌症病例的 3%。HNC 的发病率在不断增加，特别是在发展中国家，这与危险因素的变化有关。不幸的是，死亡率很高，这主要归因于在传统治疗失败的阶段进行了晚期诊断。癌症免疫疗法在抗肿瘤治疗中取得了巨大成功。检查点抑制剂（CI）抗体通过阻断抑制性受体来增强抗肿瘤活性，从而驱动肿瘤特异性 T 和 NK 细胞效应反应。自 2011 年引入以来，CI 抗体已被批准用于多种癌症类型，包括 HNC。在这里，我们研究了 CI 治疗的发展，并期待未来使用 CI 治疗 HNC 的发展。
